drugset / Trial / NCT02388464
A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a Phase 1, single-center, randomized, double-blind, single ascending dose, placebo-controlled study, in subjects aged 45-80 years with stable mild to moderate heart failure due to left ventricular systolic dysfunction, to evaluate the safety, tolerability, and pharmacokinetics of escalating single intravenous infusion doses of Bendavia™ (MTP-131).
Timeline
- Start
- 2014-07
- Primary completion
- 2015-04
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elamipretide | Peptide | 0.005 mg/kg | Intravenous |
| Subject | Elamipretide | Peptide | 0.05 mg/kg | Intravenous |
| Subject | Elamipretide | Peptide | 0.25 mg/kg | Intravenous |